Respiratory infections represent one of the leading causes of pediatric consultations and hospitalizations in Chile, where rapid etiological identification is essential for clinical decision-making. We evaluated the impact of implementing the BIOFIRE® SPOTFIRE® Respiratory (R) Panel in the pediatric Emergency Department of a public referral hospital in Santiago, using a pre–post cross-sectional design comparing two winter periods (July 2023 vs. July 2024). Clinical records, laboratory data, and operational indicators were analyzed to assess changes in diagnostic yield, turnaround time, hospitalizations, discharges, supplementary test requests, and antimicrobial use. A total of 470 patients were included (224 in 2023; 246 in 2024). The etiological detection rate increased from 58.0% to 87.8% after the implementation of Spotfire® (p < 0.0001), with marked increases in the identification of adenovirus, RSV, rhinovirus/enterovirus, and seasonal coronaviruses. Rapid molecular testing was associated with a significant rise in emergency department discharges (23.7% vs. 57.3%; p < 0.0001) and a reduction in hospitalizations (76.3% vs. 42.7%; p < 0.0001) and readmissions (9.2% vs. 0.5%; p < 0.0001). Requests for complete blood counts, chest X-rays, and antimicrobial prescriptions at discharge also decreased significantly. These effects persisted in key subgroups, including infants and children with comorbidities. In this high-demand winter setting, the BIOFIRE® SPOTFIRE® R Panel improved diagnostic performance and supported more efficient and targeted clinical management.
Purpose To evaluate the diagnostic performance and clinical utility of the BIOFIRE® Joint Infection multiplex PCR panel compared to conventional culture and 16S rRNA sequencing for the diagnosis of acute osteoarticular infections (OAI) in a Latin American setting. Methods A prospective study was conducted between August 2022 and January 2024 at two tertiary hospitals in Santiago, Chile, involving a dual cohort of 124 adults and 32 children. A total of 156 samples (synovial fluid and osteoarticular tissue) were analyzed. JI panel's performance was compared against a Composite Reference Standard (CRS) consisting of standard-of-care culture and universal 16S rRNA PCR with sequencing. Results Staphylococcus aureus was the predominant pathogen identified in both cohorts (49.3% by culture vs. 46.8% by JI). For all on-panel microorganisms, the JI panel demonstrated an overall sensitivity of 90.9% (95% CI: 81.3–96.6%) and a negative predictive value (NPV) of 92.4% (95% CI: 84.2–97.2%). In the pediatric population, the panel achieved a specificity of 95.2% and an NPV of 95.2%. Notably, the JI panel maintained high performance in 20.5% of patients with prior antibiotic exposure and successfully identified polymicrobial infections that were missed or underreported by traditional cultures. Conclusions The JI panel is a rapid, highly accurate tool for the microbiological documentation of OAIs in real-world clinical settings in Latin America. Its high NPV and rapid turnaround time (65 minutes) support its integration into diagnostic stewardship algorithms to optimize early and optimal antimicrobial therapy, particularly in pediatric cases and patients with suspected fastidious or culture-negative infections.
Thrombotic microangiopathy (TMA) is a clinical-pathological syndrome defined by microangiopathic hemolytic anemia, thrombocytopenia, and organ dysfunction, commonly affecting the kidneys. The etiologies are diverse and include genetic disorders (affecting complement proteins or other pathways, such as cobalamin metabolism), infections, autoimmune diseases, malignancies, transplantation, pregnancy, and drugs. Differentiating these causes is essential, as treatment strategies and prognoses vary widely. This consensus document, developed by a multidisciplinary group of clinicians and geneticists, provides a structured approach for evaluating TMA, with particular focus on complement-mediated TMA (C-TMA). C-TMA should be considered when TMA features persist after resolution or exclusion of secondary causes. Diagnostic confirmation relies on clinical judgment, histopathology, and a favorable response to C5 complement inhibitors, such as eculizumab or ravulizumab. This therapeutic response is considered both diagnostic and prognostic. Complement gene variants (e.g., CFH, CFI, MCP/CD46, and others) and copy number variations (e.g., CFHR1-5 deletions) are found in up to 50–60
The aim of this study was to compare the two methodological approaches recommended in ICRP Publication 135 for establishing regional diagnostic reference levels (DRLs), by applying them to a common multicountry dataset from the Optimisation of Protection in Pediatric Interventional Radiology in Latin America and the Caribbean (OPRIPALC) programme. A retrospective methodological analysis was conducted using radiation dose data collected between December 2020 and December 2023 from centres participating in OPRIPALC. After applying predefined inclusion criteria, data cleaning and trimming in accordance with ICRP-135 recommendations, 1684 paediatric interventional cardiology procedures from 11 centres in eight countries were included. Kerma area product (PKA) was selected as the primary dosimetric quantity. Regional DRLs were derived using two approaches: Method A, based on the 75th percentile of pooled patient levelPKAdata, and Method B, based on the 75th percentile of centre specific medianPKAvalues assumed to represent typical country values. DRLs were established using predefined age and weight groups. Both methodologies preserved the expected increase in DRL values with patient age, weight and procedural type. However, Method A consistently produced higher regional DRL values than Method B, particularly for therapeutic procedures and higher age or weight categories. These differences reflect the effects of data aggregation rather than differences in the underlying dataset. This study aims at illustrating the practical implications of one method over the other, rather than to recommend one methodology over the other. The findings highlight the importance of methodological transparency in regional DRL initiatives and support the applicability of the OPRIPALC framework for paediatric interventional cardiology in other regions.
Background: Death in pediatrics is one of the most challenging situations encountered by both families and healthcare professionals. Despite its clinical, ethical, and legal relevance, death by neurologic criteria (DNC), also known as brain death (BD), remains poorly characterized in pediatric intensive care units (PICUs). Brain death is defined as the irreversible loss of function of the cerebral hemispheres and brainstem and is legally equivalent to death determined by cardiopulmonary criteria. Although DNC has a low prevalence in pediatric critical care, it carries significant implications for end-of-life care, family counseling, and organ donation. To date, epidemiological data regarding pediatric DNC in Chile have been unavailable. Objective: To determine the frequency of death by neurologic criteria, describe the clinical and epidemiological characteristics of affected patients, and evaluate organ donation rates in three tertiary pediatric intensive care units in Santiago, Chile. Methods: A retrospective, observational, descriptive study was conducted in the PICUs of Luis Calvo Mackenna Hospital, Exequiel Gonzalez Cortes Hospital, and Roberto del Rio Hospital between January 1, 2014, and January 1, 2024. Medical records of deceased patients were reviewed to identify cases of areflexic coma and brain death. Demographic characteristics, admission diagnoses, mechanisms of irreversible neurological injury, diagnostic procedures, neuroimaging findings, ancillary testing, clinical evolution, and organ donation outcomes were collected and analyzed. Results: Pediatric patients with BD or death by neurologic criteria discharged from pediatric hospitals in the Metropolitan Region (MR) of Santiago during 10 years of observation were successfully characterized. This type of death accounts for 6.5% of total deaths in the PICU (34 patients), with a low proportion of donors in this population (23%), reaching nearly a quarter of patients with death by neurologic criteria.